Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31216570 | 0.90 | PDE4D (0.48) | POLBPDE4DPDE3ASLC29A1ABL1 | |
| SCHEMBL121933 | 0.89 | PDE4D (0.58) | POLBPDE4DPDE3ASLC29A1ABL1 | |
| SCHEMBL18270576 | 0.89 | PDE4D (0.58) | POLBPDE4DPDE3ASLC29A1ABL1 | |
| SCHEMBL19698977 | 0.89 | PDE4D (0.58) | POLBPDE4DPDE3ASLC29A1ABL1 | |
| SCHEMBL13160956 | 0.89 | PDE4D (0.58) | POLBPDE4DPDE3ASLC29A1ABL1 | |
| SCHEMBL19229320 | 0.88 | PDE4D (0.47) | POLBPDE4DPDE3ASLC29A1ABL1 | |
| SCHEMBL19402559 | 0.86 | P2RY6 (0.53) | ADORA3PDE4DPDE3ASLC29A1ADORA2A | |
| SCHEMBL19534943 | 0.86 | P2RY6 (0.53) | ADORA3PDE4DPDE3ASLC29A1ADORA2A | |
| SCHEMBL4357740 | 0.85 | ABL1 (0.58) | ADORA3POLBPDE4DPDE3ASLC29A1 | |
| SCHEMBL18561538 | 0.85 | ABL1 (0.58) | ADORA3POLBPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022242-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | Katholieke Universiteit Leuven, KU LEUVEN R&D (BE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022242-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | Katholieke Universiteit Leuven, KU LEUVEN R&D (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015158913-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022242-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | PNP, NTPCR, ENTPD5 | ADORA3 362/4885POLB 237/4885PDE4D 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.